Biotech News
Related news
IMTXImmatics2026-07-17 14:25 EST
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
IMTXImmatics2026-08-18 11:00 EST
Immatics Announces Second Quarter 2026 Financial Results and Business Update
KYMRKymera2026-07-27 20:01 EST
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
NRIXNurix Therapeutics2026-08-20 11:00 EST
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
BNTXBioNTech2026-08-03 09:00 EST
BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
GERNGeron2026-07-13 12:00 EST
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
Immatics
TCR-Based Solid Tumor Immunotherapy Immatics develops engineered T-cell therapies and TCR bispecifics directed against intracellular cancer targets presented by HLA molecules. PRAME Franchise The company has built multiple modalities around PRAME, a target expressed across more than 50 cancers. Anzu-cel Anzu-cel is an autologous...
Recent company news
IMTXImmatics2026-08-18 11:00 EST
Immatics Announces Second Quarter 2026 Financial Results and Business Update
IMTXImmatics2026-07-17 14:25 EST
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
IMTXImmatics2026-06-01 12:00 EST
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
IMTXImmatics2026-05-31 13:00 EST
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
IMTXImmatics2026-05-30 12:00 EST
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
Stock data
- Close
- 8.93 USD
- Market cap
- 1.37B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States